Introduction: Whole-genome sequencing of diffuse large B-cell lymphoma (DLBCL) has identified recurrent mutations involved in pathogenesis and potentially affecting response to therapy. In this pilot study, a targeted gene panel was created to identify mutations associated with relapse/refractoriness. Material and Methods: A 14-gene targeted panel was designed to sequence thirteen patients who were in remission and 8 cases that had relapsed/refractory to treatment. A paired diagnostic biopsy and a relapse biopsy were sequenced to find genes repeatedly altered in relapse. Results: A total of 751 nonsynonymous and truncating mutations were identified. Truncated mutations in NOTCH1, TNFAIP3, and CD58 were associated with poor treatment outcomes. In cases that did not respond to treatment, a high number of mutations were found in the EZH2 gene, followed by the DNA-binding domain of TP53 and MYD88. Termination mutations in the intracellular domain of NOTCH were found in 75% of non-responsive cases. Co-occurrence of loss of function mutations of TNFAIP3 and missense mutations in MYD88 was associated with a non-responsive cohort. Discussion: The study highlights mutations associated with chemotherapeutic response in DLBCL with implications for initial diagnostic biopsy response prediction.

1.
World Health Organization
.
Diffuse large B-cell lymphoma
. Available from: http://www.who.int/selection_medicines/commit-tees/expert/20/applications/DiffuseLargeBCellLymphoma.pdf [accessed 16 December 2016].
2.
Coiffier
B
,
Sarkozy
C
.
Diffuse large B-cell lymphoma: R-CHOP failure—what to do
.
Hematology 2014
the American Society of Hematology Education Program Book
2016
. p.
366
78
.
3.
Ejtehadifar
M
,
Zahedi
S
,
Gameiro
P
,
Cabeçadas
J
,
da Silva
MG
,
Beck
HC
.
Meta-analysis of MS-based proteomics studies indicates interferon regulatory factor 4 and Nucleobindin1 as potential prognostic and drug resistance biomarkers in diffuse large B cell lymphoma
.
Cells
.
2023
;
12
(
1
):
196
.
4.
Pileri
SA
,
Derenzini
E
,
Melle
F
,
Motta
G
,
Calleri
A
,
Antoniotti
P
.
Dissecting diffuse large B-cell lymphomas of the “not otherwise specified” type: the impact of molecular techniques
.
F1000Research
.
2018
7
.
5.
Alizadeh
AA
,
Eisen
MB
,
Davis
RE
,
Ma
C
,
Lossos
IS
,
Rosenwald
A
.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
.
Nature
.
2000
;
403
(
6769
):
503
11
.
6.
Melchardt
T
,
Hufnagl
C
,
Weinstock
DM
,
Kopp
N
,
Neureiter
D
,
Tränkenschuh
W
.
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
.
Oncotarget
.
2016
;
7
(
32
):
51494
502
.
7.
Juskevicius
D
,
Dirnhofer
S
,
Tzankov
A
.
Genetic background and evolution of relapses in aggressive B-cell lymphomas
.
Haematologica
.
2017
;
102
(
7
):
1139
49
.
8.
Juskevicius
D
,
Lorber
T
,
Gsponer
J
,
Perrina
V
,
Ruiz
C
,
Stenner-Liewen
F
.
Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis
.
Leukemia
.
2016
;
30
(
12
):
2385
95
.
9.
Jiang
Y
,
Redmond
D
,
Nie
K
,
Eng
KW
,
Clozel
T
,
Martin
P
.
Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas
.
Genome Biol
.
2014
;
15
(
8
):
432
17
.
10.
Lee
B
,
Lee
H
,
Cho
J
,
Yoon
SE
,
Kim
SJ
,
Park
WY
.
Mutational profile and clonal evolution of relapsed/refractory diffuse large B-cell lymphoma
.
Front Oncol
.
2021
;
11
:
628807
.
11.
Intlekofer
AM
,
Joffe
E
,
Batlevi
CL
,
Hilden
P
,
He
J
,
Seshan
VE
.
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
.
Blood Cancer J
.
2018
;
8
(
6
):
60
.
12.
Greenawalt
DM
,
Liang
WS
,
Saif
S
,
Johnson
J
,
Todorov
P
,
Dulak
A
.
Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
.
Oncotarget
.
2017
;
8
(
59
):
99237
44
.
13.
Dubois
S
,
Viailly
PJ
,
Mareschal
S
,
Bohers
E
,
Bertrand
P
,
Ruminy
P
.
Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study
.
Clin Cancer Res
.
2016
;
22
(
12
):
2919
28
.
14.
Chapuy
B
,
Stewart
C
,
Dunford
AJ
,
Kim
J
,
Kamburov
A
,
Redd
RA
.
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
.
Nat Med
.
2018
;
24
(
5
):
679
90
.
15.
Schmitz
R
,
Wright
GW
,
Huang
DW
,
Johnson
CA
,
Phelan
JD
,
Wang
JQ
.
Genetics and pathogenesis of diffuse large B-cell lymphoma
.
N Engl J Med
.
2018
;
378
(
15
):
1396
407
.
16.
Kopanos
C
,
Tsiolkas
V
,
Kouris
A
,
Chapple
CE
,
Albarca Aguilera
M
,
Meyer
R
.
VarSome: the human genomic variant search engine
.
Bioinformatics
.
2019
;
35
(
11
):
1978
80
.
17.
Thorvaldsdóttir
H
,
Robinson
JT
,
Mesirov
JP
.
Integrative Genomics Viewer [IGV]: high-performance genomics data visualization and exploration
.
Brief Bioinform
.
2013
;
14
(
2
):
178
92
.
18.
Wenzl
K
,
Manske
MK
,
Sarangi
V
,
Asmann
YW
,
Greipp
PT
,
Schoon
HR
.
Loss of TNFAIP3 enhances MYD88 L265P-driven signaling in non-Hodgkin lymphoma
.
Blood Cancer J
.
2018
;
8
(
10
):
97
.
19.
Compagno
M
,
Lim
WK
,
Grunn
A
,
Nandula
SV
,
Brahmachary
M
,
Shen
Q
.
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma
.
Nature
.
2009
;
459
(
7247
):
717
21
.
20.
Schmitz
R
,
Hansmann
ML
,
Bohle
V
,
Martin-Subero
JI
,
Hartmann
S
,
Mechtersheimer
G
.
TNFAIP3 [A20] is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
.
J Exp Med
.
2009
;
206
(
5
):
981
9
.
21.
Ngo
VN
,
Young
RM
,
Schmitz
R
,
Jhavar
S
,
Xiao
W
,
Lim
KH
.
Oncogenically active MYD88 mutations in human lymphoma
.
Nature
.
2011
;
470
(
7332
):
115
9
.
22.
Jost
PJ
,
Ruland
J
.
Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications
.
Blood
.
2007
;
109
(
7
):
2700
7
.
23.
Challa-Malladi
M
,
Lieu
YK
,
Califano
O
,
Holmes
AB
,
Bhagat
G
,
Murty
VV
.
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma
.
Cancer Cell
.
2011
;
20
(
6
):
728
40
.
24.
Berendsen
MR
,
Stevens
WB
,
van den Brand
M
,
van Krieken
JH
,
Scheijen
B
.
Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance
.
Cancers
.
2020
;
12
(
12
):
3553
.
25.
Pozzo
F
,
Bittolo
T
,
Arruga
F
,
Bulian
P
,
Macor
P
,
Tissino
E
.
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation
.
Leukemia
.
2016
;
30
(
1
):
182
9
.
26.
Duan
R
,
Du
W
,
Guo
W
.
EZH2: a novel target for cancer treatment
.
J Hematol Oncol
.
2020
;
13
(
1
):
104
12
.
27.
Li
B
,
Chng
WJ
.
EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
.
J Hematol Oncol
.
2019
;
12
:
118
3
.
28.
Duan
R
,
Du
W
,
Guo
W
.
EZH2: a novel target for cancer treatment
.
J Hematol Oncol
.
2020
;
13
(
1
):
104
2
.
29.
Gan
L
,
Yang
Y
,
Li
Q
,
Feng
Y
,
Liu
T
,
Guo
W
.
Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential
.
Biomark Res
.
2018
;
6
(
1
):
10
0
.
You do not currently have access to this content.